Prosecution Insights
Last updated: April 19, 2026
Application No. 18/041,193

PROTEASOME ENHANCERS AND USES THEREOF

Non-Final OA §102§112
Filed
Feb 09, 2023
Examiner
OTTON, ALICIA L
Art Unit
1699
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
OA Round
1 (Non-Final)
65%
Grant Probability
Moderate
1-2
OA Rounds
2y 9m
To Grant
74%
With Interview

Examiner Intelligence

Grants 65% of resolved cases
65%
Career Allow Rate
817 granted / 1260 resolved
+4.8% vs TC avg
Moderate +9% lift
Without
With
+9.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
32 currently pending
Career history
1292
Total Applications
across all art units

Statute-Specific Performance

§101
1.3%
-38.7% vs TC avg
§103
24.5%
-15.5% vs TC avg
§102
24.9%
-15.1% vs TC avg
§112
28.8%
-11.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1260 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority The instant application is a 35 US 371 National Stage filing of international application PCT/US2021/045448, filed August 10, 2021, which claims the benefit of an effective US filing date from provisional application 63/064,262, filed August 11, 2020. Information Disclosure Statements The information disclosure statements (IDS) dated February 9, 2023; July 29, 2024; November 8, 2024; February 3, 2025 and November 21, 2025 were in compliance with the provisions of 37 CFR 1.97 and 1.98. Accordingly, the IDS documents were considered and signed copies of the 1449 forms are attached. Election/Restrictions Applicant’s election of the invention of Group I, claims 51-62 (renumbered as 51-63 since there were two claims listed as 61 in the previous claim set), in the reply filed November 21, 2025 is acknowledged. Further, Applicant’s election of the species of compound 170, PNG media_image1.png 221 159 media_image1.png Greyscale in the same reply is also acknowledged. The elected species reads on claims 55, 59, 61-63, and 71-72 within the elected group. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). In accordance with the MPEP, if upon examination of the elected species, no prior art is found that would anticipate or render obvious the instant invention based on the elected species and the claims drawn to the elected species are allowable, the search of the Markush-type claim will be extended (see MPEP 803.02). If prior art is then found that anticipates or renders obvious the non-elected species, the Markush-type claim will be rejected. It should be noted that the prior art search will not be extended unnecessarily to cover all non-elected species. Should Applicant overcome the rejection by amending the claim, the amended claim will be reexamined. Id. The prior art search will be extended to the extent necessary to determine patentability of the Markush-type claim. Id. In the event prior art is found during reexamination that renders obvious or anticipates the amended Markush-type claim, the claim will be rejected and the action made final. Id. As indicated above, the Examiner searched the claimed invention based on the elected species above, wherein: the elected species was found to be allowable over the prior art. The search was expanded to include the additional species described in the rejections herein. Since the scope described herein was not found to be in condition for allowance, it has not been expanded further. Notably, no prior art was discovered over formula III of claim 55 or formula (VI) of claim 61. Status of Claims Currently, claims 55-56 and 59-80 are pending in the instant application. Claims 56, 60, 64-70 and 73-80 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a non-elected invention and/or species. Claims 55, 59, 61-63, and 71-72 read on an elected invention and species and are therefore under consideration in the instant application to the extent that they read on the elected embodiment. Claim Objections Claim 62 is objected to for depending on a rejected base claim, but would be allowable if rewritten in independent form. Claim Rejections – 35 U.S.C. § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 55, 59, 61, 63, and 71-72 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. The claims are rejected as indefinite because the variable R7 appears twice in the recited chemical formulae and is given two different definitions. In claim 55, the first instance is as a phenyl substituent PNG media_image2.png 66 59 media_image2.png Greyscale , where the variable is defined as PNG media_image3.png 30 440 media_image3.png Greyscale . The variable appears again in the definition of R4 and R14, where OR7 is listed as an aryl or heteroaryl substituent, and is set forth with a new definition PNG media_image4.png 53 663 media_image4.png Greyscale . In claim 59, the first instant is as a nitrogen substituent depicted in formula (V), where it is defined as PNG media_image5.png 77 661 media_image5.png Greyscale . The variable appears again in the definition of R4 and R14, where OR7 is listed as an aryl or heteroaryl substituent, and is set forth with a new definition PNG media_image4.png 53 663 media_image4.png Greyscale . In 61, the first instance is as a phenyl substituent PNG media_image6.png 80 65 media_image6.png Greyscale , where the variable is defined as PNG media_image3.png 30 440 media_image3.png Greyscale . The variable appears again in the definition of R16 and R18, where OR7 is listed as an aryl or heteroaryl substituent, and is set forth with a new definition PNG media_image4.png 53 663 media_image4.png Greyscale . Any given variable can only have one definition in a chemical formula to avoid confusion and ambiguity in the structure. Appropriate clarification/correction is required. The claims are rejected because they recite the limitation that R14, R7 and R4 may be S, S(O) or S(O)2. These definitions represent a divalent substituent (i.e. another chemical moiety would be required in order to fill the valence of each of these groups), but the substituents are defined for a monovalent position. It is unclear how this monovalent position could be defined by substituents which are necessarily divalent without also defining what else the moieties are bound to. Any dependent claims that do not recite a particular compound or list of compounds by exact structure does not remedy this issue; therefore, the dependent claims are also rejected. Claim Rejections - 35 USC §102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. It is noted that with respect to the rejection below, for the purposes of determining if a reference is a “printed publication” for the purposes of 102(a)(1), MPEP 2128 states the following: PNG media_image7.png 99 480 media_image7.png Greyscale Specifically regarding electronic publications, such as online databases, as prior art the following is noted: PNG media_image8.png 78 750 media_image8.png Greyscale where “prior art disclosures…on an on-line database are considered to be publicly available as of the date the item was publicly posted.” Since the database entries below list the dates that the compounds were entered into the on-line database, the compounds were made publicly available as of those dates in the citation, and the claims are anticipated. Claim(s) 59 and 71 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by the STN Registry database entry for CAS RN 1016843-01-8, which has an entry date of 24 April 2008. Since the entry date represents the date that the compound entered a publicly available database on STN, this represents the date that the compound was made accessible to the public. The STN Registry database entry listed above discloses the compound PNG media_image9.png 169 260 media_image9.png Greyscale which reads on the formula (V) where G is a methylene group; R7 and R8 together with the nitrogen form a heterocycle (piperazine); and R13 is PNG media_image10.png 81 165 media_image10.png Greyscale where each of W, X, Y and Z is C-R14; R14 is H; and p is 0. Since the compound disclosed in the prior art has the same structure as the instantly claimed compound, each and every required element of the claim is taught and the claim is anticipated. With respect to the instantly claimed pharmaceutical composition, it is noted that the prior art discloses molar solubility data which describes the anticipatory compound in unbuffered water, which is a pharmaceutically acceptable carrier. Accordingly, the claims are anticipated. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alicia L. Otton whose telephone number is (571)270-7683. The examiner can normally be reached on Monday - Thursday, 8:00-6:00. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Mr. Fereydoun Sajjadi can be reached on 571-272-3311. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ALICIA L OTTON/Primary Examiner, Art Unit 1699
Read full office action

Prosecution Timeline

Feb 09, 2023
Application Filed
Nov 21, 2025
Response after Non-Final Action
Jan 10, 2026
Non-Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600701
N-ACYLHYDRAZONIC COMPOUNDS, USE IN THE TREATMENT OF AMYLOID AND NON-AMYLOID DEGENERATIVE AGGREGOPATHIES, AND PHARMACEUTICAL COMPOSITION
2y 5m to grant Granted Apr 14, 2026
Patent 12600709
NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12588678
OXAZOLINE COMPOUND, SYNTHESIS METHOD THEREFOR AND APPLICATION THEREOF
2y 5m to grant Granted Mar 31, 2026
Patent 12583887
PSMA Imaging Agents
2y 5m to grant Granted Mar 24, 2026
Patent 12583840
METHOD FOR THE PREPARATION OF ANDROGEN RECEPTOR ANTAGONISTS AND INTERMEDIATES THEREOF
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
65%
Grant Probability
74%
With Interview (+9.1%)
2y 9m
Median Time to Grant
Low
PTA Risk
Based on 1260 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month